Compare AstraZeneca plc (AZN) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares MBS ETF — how do they compare? AstraZeneca plc trades at $166.61 (market cap $253.13B), while iShares MBS ETF trades at $93.69. The key difference: AstraZeneca plc pays a 1.92% dividend while iShares MBS ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| AZN | MBB | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | — |
52-Week High | $209.48 | $96.91 |
52-Week Low | $137.44 | $92.46 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
MBB, the iShares MBS ETF, trades at $93.26, down 0.49% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oversold oscillators suggest potential for a near-term bounce. Recent news highlights institutional activity, with some firms increasing stakes while others reduced positions. The ETF continues its dividend distributions, with the latest payment scheduled for July 2026.
The outlook for MBB is mixed, balancing a defensive income stream from mortgage-backed securities against interest rate sensitivity. The primary opportunity lies in its monthly dividend yield, appealing for income-focused investors. Key risks include Federal Reserve policy shifts impacting bond valuations and broader economic conditions affecting the housing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
